CD38

Target id: 2766

Nomenclature: CD38

Family: CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     CD38 has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 300 4p15.32 CD38 CD38 molecule 4
Mouse - 304 5 B3 Cd38 CD38 antigen
Rat 1 303 14q21 Cd38 CD38 molecule
Previous and Unofficial Names
ADP-ribosyl cyclase 1
Database Links
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of CD38 with a novel CD38-targeting antibody SAR650984 (=isatuximab).
PDB Id:  4CMH
Ligand:  isatuximab
Resolution:  1.53Å
Species:  Human
References:  2

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
isatuximab Hs Binding 8.5 – 10.0 pKd 5
pKd 8.5 – 10.0 (Kd 3x10-9 – 1x10-10 M) [5]
daratumumab Hs Antagonist 8.2 pKd 1
pKd 8.2 (Kd 6.06x10-9 M) [1]
Immunopharmacology Comments
CD38 is a type II transmembrane glycoprotein, widely expressed on immune cells and involved in cell adhesion and signal transduction. Its extracellular domain acts as an ectoenzyme, catalyzing the conversion of nicotinamide adenine dinucleotide (NAD+) into nicotinamide, adenosine diphosphate-ribose (ADPR), and cyclic ADPR. Expression of CD38 is tightly regulated during B-cell development and maturation [3]. In chronic lymphocytic leukemia (CLL) expression of CD38 suggests a poor prognosis. Clinically, CD38 is the target of the approved monoclonal antibody daratumumab (for multiple myeloma).
Immuno Cell Type Associations
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   monocyte (CL:0000576)
macrophage (CL:0000235)
Comment: 
References: 
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Comment: 
References: 
Immuno Cell Type:  B cells
Cell Ontology Term:  
Comment: 
References: 
Immuno Cell Type:  T cells
Cell Ontology Term:  
Comment: 
References: 
Immuno Cell Type:  Natural killer cells
Cell Ontology Term:  
Comment: 
References: 
Immuno Process Associations
Immuno Process:  B cell (activation)
Immuno Process ID:  5
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  positive regulation of B cell proliferation (GO:0030890) IMP
References: 
Immuno Process:  Immune regulation
Immuno Process ID:  6
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  positive regulation of B cell proliferation (GO:0030890) IMP
B cell receptor signaling pathway (GO:0050853) IMP
References: 
Immuno Process:  Cellular signalling
Immuno Process ID:  11
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  positive regulation of B cell proliferation (GO:0030890) IMP
B cell receptor signaling pathway (GO:0050853) IMP
References: 
Immuno Process:  Cytokine production & signalling
Immuno Process ID:  9
Comment: 
GO Annotation:  Associated to GO processes, IEA only
GO Processes:  response to interleukin-1 (GO:0070555) IEA
References: 

References

Show »

1. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010) Antibodies Against Cd38 For Treatment Of Multiple Myeloma. Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.

2. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C et al.. (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin. Cancer Res.20 (17): 4574-83. [PMID:24987056]

3. Hamblin TJ. (2003) CD38: what is it there for?. Blood102: 1939-1940.

4. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol.144 (7): 2811-5. [PMID:2319135]

5. Park PU, Bartle L, Skaletskaya A, Golmakher V, Tavares D, Deckert J, Milol V, Blanc V. (2011) Novel anti-cd38 antibodies for the treatment of cancer. Patent number: US20110262454 A1. Assignee: Sanofi-Aventis. Priority date: 20/08/2015. Publication date: 27/10/2011.

How to cite this page

CD molecules: CD38. Last modified on 15/05/2017. Accessed on 20/10/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2766.